Cold-stored leukoreduced CPDA-1 whole blood: in vitro quality and hemostatic properties.
Adenine
/ chemistry
Blood
/ drug effects
Blood Platelets
/ cytology
Blood Preservation
/ methods
Blood Specimen Collection
/ methods
Citrates
/ chemistry
Cold Temperature
Filtration
/ methods
Glucose
/ chemistry
Hemolysis
/ drug effects
Hemostasis
/ drug effects
Humans
In Vitro Techniques
Leukocyte Reduction Procedures
/ methods
Phosphates
/ chemistry
Platelet Aggregation
/ drug effects
Platelet Count
Quality Control
Refrigeration
/ methods
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
30
08
2019
revised:
13
02
2020
accepted:
17
02
2020
pubmed:
19
3
2020
medline:
9
9
2020
entrez:
19
3
2020
Statut:
ppublish
Résumé
Some jurisdictions require leukoreduction of cellular blood components. The only whole blood collection set with a platelet-saving filter uses citrate-phosphate-dextrose (CPD) as storage solution. Substituting CPD with citrate-phosphate-dextrose-adenine (CPDA-1) increases shelf life from 21 to 35 days. This would simplify prehospital and rural resupply and reduce wastage. We investigated in vitro quality and hemostatic properties of CPDA-1 whole blood leukoreduced with a platelet-saving filter. CPDA-1 whole blood was leukoreduced using a platelet-saving filter and stored 35 days. EDQM requirements, hematology, metabolic parameters, thromboelastography, light transmission aggregometry, fibrinogen, factor VIII, and interleukin-6 were measured on Days 0, 1, 14, 21, and 35 and compared to non-leukoreduced blood. All units met EDQM requirements. Leukoreduction yielded residual white blood cell count <1 × 10 Leukoreducing CPDA-1 whole blood with a platelet-saving filter did not compromise hemostatic properties. We encourage development of a single bag CPDA-1 whole blood collection set with in-line platelet-saving filter.
Sections du résumé
BACKGROUND
Some jurisdictions require leukoreduction of cellular blood components. The only whole blood collection set with a platelet-saving filter uses citrate-phosphate-dextrose (CPD) as storage solution. Substituting CPD with citrate-phosphate-dextrose-adenine (CPDA-1) increases shelf life from 21 to 35 days. This would simplify prehospital and rural resupply and reduce wastage. We investigated in vitro quality and hemostatic properties of CPDA-1 whole blood leukoreduced with a platelet-saving filter.
STUDY DESIGN AND METHODS
CPDA-1 whole blood was leukoreduced using a platelet-saving filter and stored 35 days. EDQM requirements, hematology, metabolic parameters, thromboelastography, light transmission aggregometry, fibrinogen, factor VIII, and interleukin-6 were measured on Days 0, 1, 14, 21, and 35 and compared to non-leukoreduced blood.
RESULTS
All units met EDQM requirements. Leukoreduction yielded residual white blood cell count <1 × 10
CONCLUSION
Leukoreducing CPDA-1 whole blood with a platelet-saving filter did not compromise hemostatic properties. We encourage development of a single bag CPDA-1 whole blood collection set with in-line platelet-saving filter.
Substances chimiques
CPDA solutions
0
Citrates
0
Phosphates
0
citrate phosphate dextrose
51404-37-6
Glucose
IY9XDZ35W2
Adenine
JAC85A2161
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1042-1049Informations de copyright
© 2020 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.
Références
Spinella PC, Cap AP. Prehospital hemostatic resuscitation to achieve zero preventable deaths after traumatic injury. Curr Opin Hematol 2017;24:529-35.
Cap AP, Beckett A, Benov A, et al. Whole blood transfusion. Mil Med 2018;183:44-51.
Ministry of Health and Care Services. Regulations on the collection, testing, processing, storage and distribution of human blood and blood components FOR-2005-02-04-80, 2019. Oslo, Norway: Ministry of Health and Care Services.
Fung MK, Eder AF, Spitalnik SL, et al. AABB technical manual. 19th ed. Bethesda, MD: AABB; 2017.
Sivertsen J, Braathen H, Lunde THF, et al. Preparation of leukoreduced whole blood for transfusion in austere environments; effects of forced filtration, storage agitation, and high temperatures on hemostatic function. J Trauma Acute Care Surg 2018;84:S93-S103.
Remy KE, Yazer MH, Saini A, et al. Effects of platelet sparing leukocyte reduction and agitation methods on in vitro measures of hemostatic function in cold-stored whole blood. J Trauma Acute Care Surg 2018;84(6S Suppl 1):S104-14.
Vucic M, Stanojkovic Z, Antic A, et al. Evaluation of platelet activation during storage in leukocyte-depleted platelet concentrates. Bosn J Basic Med Sci 2018;1:29-34.
Turner CP, Sutherland J, Wadhwa M, et al. In vitro function of platelet concentrates prepared after filtration of whole blood or buffy coat pools. Vox Sang 2005;88:164-71.
Paunovic D, van der Meer P, Kjeldsen-Kragh J, et al. Multicenter evaluation of a whole-blood filter that saves platelets. Transfusion 2004;44:1197-203.
Lozano ML, Perez-Ceballos E, Rivera J, et al. Evaluation of a new whole-blood filter that allows preparation of platelet concentrates by platelet-rich plasma methods. Transfusion 2003;43:1723-8.
Cardigan R, Sutherland J, Garwood M, et al. The effect of leucocyte depletion on the quality of fresh-frozen plasma. Br J Haematol 2001;114:233-40.
Meledeo MA, Peltier GC, McIntosh CS, et al. Optimizing whole blood storage: hemostatic function of 35-day stored product in CPD, CP2D, and CPDA-1 anticoagulants. Transfusion 2019;59:1549-59.
Peck CC, Moore GL, Bolin RB. Adenine in blood preservation. Crit Rev Clin Lab Sci 1981;13:173-212.
Valeri CR, Valeri DA, Gray A, et al. Red blood cell concentrates stored at 4 degrees C for 34 days in CPDA-1, CPDA-2, or CPDA-3 anticoagulant-preservative, biochemically modified, and frozen and stored in the polyvinyl chloride plastic primary collection bag with 40% W/V glycerol at −80 degrees C. Transfusion 1982;22:102-6.
Valeri CR, Valeri DA, Gray A, et al. Viability and function of red blood cell concentrates stored at 4 degrees C for 35 days in CPDA-1, CPDA-2, or CPDA-3. Transfusion 1982;22:210-6.
Guide to the preparation, use and quality assurance of blood components. Strasbourg, France: European Directorate for the Quality of Medicines & HealthCare; 2017.
Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost 2013;11:1183-9.
Thomas KA, Shea SM, Yazer MH, et al. Effect of leukoreduction and pathogen reduction on the hemostatic function of whole blood. Transfusion 2019;59:1539-48.
Remy KE, Yazer MH, Saini A, et al. Effects of platelet-saving leukocyte reduction and agitation methods on in vitro measures of hemostatic function in cold-stored whole blood. J Trauma Acute Care Surg 2018;84:S104-14.
Braathen H, Sivertsen J, Lunde THF, et al. In vitro quality and platelet function of cold and delayed cold storage of apheresis platelet concentrates in platelet additive solution for 21 days. Transfusion 2019;59:2652-61.
Siletz A, Burruss S, Gruber T, et al. Leukocyte filtration lesion impairs functional coagulation in banked whole blood. J Trauma Acute Care Surg 2017;83:420-6.
Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2014;54:1389-405 quiz 8.
Bouzat P, Ageron FX, Charbit J, et al. Modelling the association between fibrinogen concentration on admission and mortality in patients with massive transfusion after severe trauma: an analysis of a large regional database. Scand J Trauma Resusc Emerg Med 2018;26:55.
Seebold JA, Campbell D, Wake E, et al. Targeted fibrinogen concentrate use in severe traumatic haemorrhage. Crit Care Resusc 2019;21:171-8.
Muylle L, Wouters E, Peetermans ME. Febrile reactions to platelet transfusion: the effect of increased interleukin 6 levels in concentrates prepared by the platelet-rich plasma method. Transfusion 1996;36:886-90.
Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625-8.
Weisbach V, Wanke C, Zingsem J, et al. Cytokine generation in whole blood, leukocyte-depleted and temporarily warmed red blood cell concentrates. Vox Sang 1999;76:100-6.
Jacobi KE, Wanke C, Jacobi A, et al. Determination of eicosanoid and cytokine production in salvaged blood, stored red blood cell concentrates, and whole blood. J Clin Anesth 2000;12:94-9.
Shukla R, Patel T, Gupte S. Release of cytokines in stored whole blood and red cell concentrate: effect of leukoreduction. Asian J Transfus Sci 2015;9:145-9.
Nielsen HJ, Reimert CM, Pedersen AN, et al. Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood. Transfusion 1996;36:960-5.